2019 The circadian timing system regulates daily oscillations in behavior and physiologic functions. There is a growing realization that long-term circadian timing system dysfunction has serious health consequences and may directly influence various disease pathologies. This project will test the hypothesis that poor circadian rhythms mediated by a dysfunctional hypothalamic central ...
December 13, 2018
A US News and World Report article profiles a new test to determine the effectiveness of Alzheimer’s drugs developed by Cure Alzheimer’s Fund’s Dr. David Holtzman. The stable isotope-linked kinetics or SILK test quickly reveals whether medication is working to limit the harmful protein amyloid beta. Click here to read full ...
June 30, 2009
Anne, Mom, Grammy, Gracie My mother died last February of Alzheimerās Disease.Ā Ā I have been surprised at how hard it has been to lose her.Ā I thought I was ready . . . she was, after all, declining.Ā I was not ready.Ā I thought that when she died I would feel ...
March 8, 2015
The goal of this project is to develop genetically modified human neural progenitor cells that can replicate Alzheimerās disease pathology in in vitro and in vivo conditions in order to develop and test Alzheimer disease drugs in human brain cells. This work represents a potential major breakthrough in the use of ...
November 9, 2011
Neurofibrillary tangles (NFTs) and neurodegeneration occur only in very specific regions at early stages of Alzheimerās disease (AD), while many regions remain virtually unaffected. Using the bacTRAP technology the lab developed to isolate mRNAsĀ from specific neuron types, we molecularly profiled these very vulnerable neurons and other neurons that are much ...
September 24, 2015
The well-known behavioral symptoms of Alzheimerās disease (AD) are caused by the loss of connections, or synapses, among neurons that control memory and cognition, and by the death of those neurons. A major goal of our labs is to unravel the seminal molecular pathways that convert normal healthy neurons into ...
September 28, 2015
The human gut contains a myriad of microorganisms collectively referred to as theĀ microbiome. We propose to investigate if the microbiome may modulate the progression of early Alzheimerās disease (AD) pathology. More than a century ago, the Nobel laureate Elie Metchnikoff postulated that āgood gut bacteriaā may delay senility and have beneficial ...
November 3, 2015
Immunotherapy is a leading strategy for preventing cognitive decline in Alzheimerās disease. Administering a monoclonal antibody to beta amyloid aggregates in patients with mild cognitive impairment showed some positive impact on cognitive decline over the course of a year in a clinical trial, but effective dosages are tied to negative ...
December 6, 2016
Alzheimerās disease, as the leading cause of dementia, has become a growing epidemic in our aging society. While aging is the greatest risk factor for AD development, a growing list of genetic and environmental factors also contributes to the risk. Among them, a gene called APOE is the strongest genetic ...
July 25, 2017
Dr. Paul Greengard was a pioneer in understanding how brain cells communicate, and his work was rewarded with the Nobel Prize in Physiology or Medicine. Cure Alzheimerās Fund was privileged to begin working with Dr. Greengard in 2006. So many of the researchers funded by CureAlz looked to Dr. Greengard for ...
September 5, 2017
